Why Chimerix & Infineon Stocks Are Rising Today?

2 min read | January 11, 2021 09:18 AM EST | By Hina Chowdhary

Why Chimerix & Infineon Stocks Are Rising Today?

Chimerix Inc’s Latest Acquisition

Chimerix’s stock price surge on Friday came as it announced its decision to acquire cancer research and biotechnology firm, Oncoceutics Inc. The US$ 78-million deal will see a transaction in both Chimerix stocks and cash, US$ 25 million of which will be paid upon the completion of the deal.

The Durham-based company added that Oncoceutics is currently working on the clinical trial of its lead candidate ONC-201, an orally administered treatment meant to fight an aggressive form of brain cancer known as recurrent glioma. The ONC-201 program is expected to show crucial data by this year.

Chimerix has struggled over the past year following disappointing results from the clinical trials for its antiviral medication ‘brincidofovir’. With Oncoceutics' pipeline of trials, the company is attempting to undo some of its loses.

©Kalkine Group 2021

Infineon Technologies’ A Market Leader?

Infineon stocks began to soar on Friday following the news that a study from last year projects the company as a leader in the micro-electromechanical system (MEMS) microphones market based on MEM chip unit sales. The study, conducted by tech research firm Omdia, said that Infineon is at the top spot with a nearly four per cent lead from the second place and over 37 per cent ahead of the third spot.

Shares of this German company have risen steadily since the March lows last year, climbing over 76 per cent in the last six months and about 74 per cent in 2020.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.